Introduction {#sec1_1}
============

Most melanomas, especially of the skin, are easily diagnosed. However, some variants have a tendency to mimic the morphology of a variety of epithelial and soft tissue neoplasms. Rhabdoid melanoma was first described by Bittesini et al. \[[@B1]\] in 1992, and its histological features include abundant eosinophilic cytoplasm, round vesicular nuclei with prominent, centrally placed nucleoli and large hyaline cytoplasmic inclusions.

Primary rhabdoid melanoma (PRM) is a rare variant of malignant melanoma. To the best of our knowledge, only 7 cases have been reported in the literature. Herein, we report a case of primary amelanotic rhabdoid melanoma and review the clinicopathological features of previous cases of PRMs.

Case Report {#sec1_2}
===========

A 63-year-old Japanese man presented with a nonpigmented red granular tumor without peripheral pigmented macules on the left heel (fig. [1a](#F1){ref-type="fig"}). The tumor measured 21 × 18 mm in size and had been detected about 1 year before. The clinical differential diagnosis included squamous cell carcinoma, poroma, porocarcinoma, metastatic skin cancer, pyogenic granuloma and amelanotic melanoma. Dermatoscopic assessment revealed a homogenous pattern with milky red areas and polymorphous vessels (fig. [1b](#F1){ref-type="fig"}). An incisional biopsy was performed at another institution, and a diagnosis of squamous cell carcinoma was made. He was referred to our department for treatment. CT and MRI were performed for preoperative evaluation and detected no nodal disease or distant metastasis and no other neoplasms. Hence, the patient subsequently underwent excision of the tumor with a wide margin and sentinel lymph node biopsy on the left groin.

Light microscopic examination revealed a tumor mass composed entirely of polygonal neoplastic cells predominantly resembling pulmonary alveoli with ulceration (fig. [1c](#F1){ref-type="fig"}). Polygonal neoplastic cells were also discohesive with bizarre nuclei, prominent nucleoli and large hyaline cytoplasmic inclusions (fig. [1d](#F1){ref-type="fig"}). No melanin pigment was present. An intraepidermal component was observed in multiple sections. The tumor\'s Breslow thickness measured 4.0 mm, and it had a Clark level of 3. Also, mitoses per mm^2^ was \>1. Pathological examination revealed no regression and lymphovascular invasion. Infiltration of lymphocytes at the base of the tumor was mild. Similar neoplastic atypical cells were observed in the sentinel nodes, forming nests. The neoplastic cells were strongly and diffusely positive for S-100, MART-1 (fig. [2a](#F2){ref-type="fig"}), HMB-45 (fig. [2b](#F2){ref-type="fig"}) and vimentin (fig. [2c](#F2){ref-type="fig"}) and negative for synaptophysin, AE1/AE3 and desmin (fig. [2d](#F2){ref-type="fig"}).

We diagnosed this tumor as primary cutaneous amelanotic rhabdoid melanoma with characteristic features of histological examinations and immunohistochemical analysis. Clinicopathological findings resulted in a classification of stage IIIC disease in accord with the criteria set forth by the American Joint Committee on Cancer. Based on the results of the sentinel node biopsy, the patient underwent groin dissection and adjuvant combination chemotherapy that included dacarbazine. Finally, nodal involvements were found in 4 of 18 dissected nodes. At follow-up 44 months after the initial melanoma diagnosis, lung metastasis occurred. The patient has received a targeted therapy by nivolumab, which is a human programmed death receptor-1 blocking antibody at present. Incidentally, no somatic mutations in BRAF were found in this case.

Discussion {#sec1_3}
==========

The typical malignant rhabdoid tumor is a pediatric malignancy occurring in the kidney, first described by Haas et al. \[[@B2]\] and thought to represent a rhabdomyosarcomatous variant of Wilms tumor. Presently, the malignant rhabdoid tumor is recognized as a separate entity due to a lack of rhabdomyoblastic ultrastructural features. Since first described, the presence of extrarenal malignant rhabdoid tumors has been reported in soft tissue as well as in various organs such as the brain, lung, liver, colon, ovary, uterus, and skin \[[@B3]\].

Rhabdoid melanoma was first described by Bittesini et al. in 1992 \[[@B1]\]. Since then, over 40 cases of metastatic or recurrent rhabdoid melanoma have been reported, but only 7 cases of PRM appear in the literature \[[@B4],[@B5],[@B6],[@B7],[@B8]\]. Here we report the first Japanese case of PRM in English. Clinicopathological characteristics of all PRMs are documented in table [1](#T1){ref-type="table"}.

Six out of those cases showed nodular melanoma in clinical subtypes noteworthy. Moreover, 5 of these were amelanotic melanomas. Our case had both typical features of nodular melanoma and amelanotic melanoma. Furthermore, Chung et al. \[[@B8]\] analyzed the clinicopathological features of 31 specimens from 29 cases of metastatic rhabdoid melanoma and reported that 61% of the specimens were exclusively amelanotic and included 15 tumors with purely rhabdoid features. In both primary and metastatic cases, rhabdoid melanoma also tended to be amelanotic \[[@B9]\]. Although the mechanisms are still unknown, melanoma cells may lack the ability to produce melanin in the process of rhabdoid transdifferentiation.

In this case, HMB-45 staining was clearly positive and made the diagnosis of melanoma easier. In the review of metastatic rhabdoid melanoma by Chung et al. \[[@B8]\], 41% of specimens were positive for HMB-45. Low HMB-45 stainability was also found in previous PRM cases (table [1](#T1){ref-type="table"}). The reasons for this phenomenon are controversial; however, we should know a lack of HMB-45 staining is a characteristic feature of rhabdoid melanoma as well as a lack of melanin pigment.

One might expect rhabdoid melanomas to follow an aggressive course because they behave like renal and extrarenal rhabdoid tumors. However, based on the previous review, rhabdoid melanomas appear to behave no more aggressively than common melanomas \[[@B3]\]. A confounding factor in our case is the development of lung metastasis approximately 4 years after the initial examination. Because PRMs are so rare and the number of reported cases is so small, additional research is needed to determine the prognosis of this disease with some degree of accuracy.

Rhabdoid melanoma is a rare variant of melanoma, and many pathological and biological problems have yet to be resolved. Recognition of this rare entity is important to avoid confusion both in diagnosis and in the subsequent direction of therapy.
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![**a** A nonpigmented red granular tumor without peripheral pigmented macules on the left heel. The tumor measured 21 × 18 mm in size. **b** Dermatoscopy revealed a homogenous pattern with milky red areas and polymorphous vessels. **c** Light microscopic examination revealed a tumor mass composed entirely of polygonal neoplastic cells predominantly resembling pulmonary alveoli. **d** Polygonal neoplastic cells were also discohesive with bizarre nuclei, prominent nucleoli and large hyaline cytoplasmic inclusions. Hematoxylin and eosin. Original magnification. **c** ×40. **d** ×400.](cde-0007-0292-g01){#F1}

![Immunohistochemically, the melanoma cells were positive for MART-1 (**a**), HMB-45 (**b**) and vimentin (**c**), and negative for desmin (**d**). Original magnification. **a-d** ×40.](cde-0007-0292-g02){#F2}

###### 

Clinicopathological characteristics of reported PRM

  Case \[Ref.\]   Age/sex     Location       Clinical subtype   Amela-notic   S-100   MART-1   HMB-45   Vimentin   Desmin   αSMA   Synapto-physin   Follow-up or survival time   TT, mm   Epidermal components
  --------------- ----------- -------------- ------------------ ------------- ------- -------- -------- ---------- -------- ------ ---------------- ---------------------------- -------- ----------------------
  1 \[[@B5]\]     36/female   Scalp          NM                 yes           \+      ND       −        \+         −        −      ND               12 mo                        ND       no
  2 \[[@B5]\]     30/female   Thigh          NM                 yes           \+      ND       −        \+         −        −      ND               60 mo                        ND       yes
  3 \[[@B5]\]     59/male     Back           NM                 yes           \+      ND       −        \+         −        \+     ND               ND                           ND       no
  4 \[[@B6]\]     07/male     Deltoid area   ND                 yes           \+      ND       ND       \+         ND       ND     ND               09 mo                        ND       yes
  5 \[[@B4]\]     41/male     Scalp          ND                 ND            \+      \+       ND       ND         ND       ND     ND               06 mo, ^†^                   6        yes
  6 \[[@B7]\]     74/male     Back           NM                 ND            \+      −        −        \+         ND       ND     ND               12 mo                        ND       no
  7 \[[@B8]\]     54/male     Forearm        NM                 no            \+      ND       \+       \+         −        −      −                04 mo                        9        ND
  Our                                                                                                                                                                                     
  case            63/male     Sole           NM                 yes           \+      \+       \+       \+         −        −      −                44 mo                        4        yes

NM = Nodular melanoma; ND = not described or not done; αSMA = alpha smooth muscle antigen; TT = tumor thickness.
